Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wiel C M de Lange

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Advances in Experimental Medicine and Biology|August 15, 2003
Immune reactivation and paradoxical worsening in an HIV-infected tuberculosis patientWiel C M de Lange
American Journal of Respiratory and Critical Care Medicine|August 7, 2007
Impact of new American Thoracic Society diagnostic criteria on management of nontuberculous mycobacterial infectionJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
Journal of Gastroenterology and Hepatology|November 13, 2007
Antituberculosis drug-induced hepatotoxicity: concise up-to-date reviewAlma Tostmann, Martin J Boeree, Rob E Aarnoutse, et al.
The European Respiratory Journal|March 25, 2016
Implementing tuberculosis entry screening for asylum seekers: the Groningen experienceOnno W Akkerman, Wiel C M de Lange, Elisabeth H Schölvinck, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Clinical relevance of Mycobacterium szulgai in The NetherlandsJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
International Journal of Mycobacteriology|January 4, 2017
Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoringMathieu S Bolhuis, Onno W Akkerman, Marieke G G Sturkenboom, et al.
The European Respiratory Journal|August 24, 2019
Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsulesMathieu S Bolhuis, Tjip S van der Werf, Huib A M Kerstjens, et al.
Emerging Infectious Diseases|March 8, 2008
Mycobacterium xenopi clinical relevance and determinants, the NetherlandsJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 10, 2016
Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurementsMarieke G G Sturkenboom, Mathieu S Bolhuis, Onno W Akkerman, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2015
Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the futureMarieke G G Sturkenboom, Onno W Akkerman, Mathieu S Bolhuis, et al.
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Advances in Experimental Medicine and Biology|August 15, 2003
Immune reactivation and paradoxical worsening in an HIV-infected tuberculosis patientWiel C M de Lange
American Journal of Respiratory and Critical Care Medicine|August 7, 2007
Impact of new American Thoracic Society diagnostic criteria on management of nontuberculous mycobacterial infectionJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
Journal of Gastroenterology and Hepatology|November 13, 2007
Antituberculosis drug-induced hepatotoxicity: concise up-to-date reviewAlma Tostmann, Martin J Boeree, Rob E Aarnoutse, et al.
The European Respiratory Journal|March 25, 2016
Implementing tuberculosis entry screening for asylum seekers: the Groningen experienceOnno W Akkerman, Wiel C M de Lange, Elisabeth H Schölvinck, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 2008
Clinical relevance of Mycobacterium szulgai in The NetherlandsJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
International Journal of Mycobacteriology|January 4, 2017
Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoringMathieu S Bolhuis, Onno W Akkerman, Marieke G G Sturkenboom, et al.
The European Respiratory Journal|August 24, 2019
Treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring: first experiences with sub-300 mg linezolid dosages using in-house made capsulesMathieu S Bolhuis, Tjip S van der Werf, Huib A M Kerstjens, et al.
Emerging Infectious Diseases|March 8, 2008
Mycobacterium xenopi clinical relevance and determinants, the NetherlandsJakko van Ingen, Martin J Boeree, Wiel C M de Lange, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 10, 2016
Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurementsMarieke G G Sturkenboom, Mathieu S Bolhuis, Onno W Akkerman, et al.
Antimicrobial Agents and Chemotherapy|March 13, 2015
Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the futureMarieke G G Sturkenboom, Onno W Akkerman, Mathieu S Bolhuis, et al.
Pageof 5